Armata Pharmaceuticals, Inc.ARMPNYSE
Loading
Year-over-year SG&A expense growth
| Period | Value |
|---|---|
| Q4 2025 | 24.99% |
| Q3 2025 | 4.66% |
| Q2 2025 | -19.49% |
| Q1 2025 | -2.11% |
| Q4 2024 | 2.44% |
| Q3 2024 | -5.67% |
| Q2 2024 | 8.21% |
| Q1 2024 | -0.03% |
| Q4 2023 | -5.44% |
| Q3 2023 | 56.37% |
| Q2 2023 | -15.29% |
| Q1 2023 | 40.22% |
| Q4 2022 | 15.95% |
| Q3 2022 | -25.06% |
| Q2 2022 | 5.04% |
| Q1 2022 | -10.80% |
| Q4 2021 | 25.74% |
| Q3 2021 | -17.34% |
| Q2 2021 | -0.56% |
| Q1 2021 | 8.80% |
| Q4 2020 | 7.15% |
| Q3 2020 | -6.49% |
| Q2 2020 | -9.12% |
| Q1 2020 | 24.56% |
| Q4 2019 | -53.62% |
| Q3 2019 | 80.50% |
| Q2 2019 | 50.87% |
| Q1 2019 | -6.44% |
| Q4 2018 | 15.60% |
| Q3 2018 | -6.18% |
| Q2 2018 | -14.52% |
| Q1 2018 | 22.86% |
| Q4 2017 | -19.71% |
| Q3 2017 | -42.06% |
| Q2 2017 | 46.68% |
| Q1 2017 | 23.49% |
| Q4 2016 | -13.70% |
| Q3 2016 | -27.34% |
| Q2 2016 | -7.30% |
| Q1 2016 | 42.69% |